Permanent Pacemaker and Implantable Cardioverter Defibrillator Infection

A Population-Based Study

Daniel Z. Uslan, MD; Muhammad R. Sohail, MD; Jennifer L. St. Sauver, PhD; Paul A. Friedman, MD; David L. Hayes, MD; Sarah M. Stoner, MS; Walter R. Wilson, MD; James M. Steckelberg, MD; Larry M. Baddour, MD

Background: The incidence of cardiac device infection is not well understood. Bloodstream infection (BSI) in patients with permanent pacemakers or implantable cardioverter-defibrillators (hereafter, defibrillators) may reflect device infection.

Methods: Retrospective, population-based cohort study of all adult patients with cardiac devices who resided in Olmsted County, Minnesota, from 1975 to 2004. The medical linkage-system of the Rochester Epidemiology Project and standardized criteria were used to identify all cases of BSI and device infection. The incidence of device infection was calculated with person-years of follow-up after device implantation.

Results: A total of 1524 patients with cardiac devices were included in the cohort. Total person-time of follow-up was 7578 years. The incidence of definite device infection was 1.9 per 1000 device-years (95% confidence interval [CI], 1.1-3.1). The incidence of pocket infection without BSI was 1.37 per 1000 device-years (95% CI, 0.62-3.05), and pocket infection with BSI or device-related endocarditis 1.14 per 1000 device years (95% CI, 0.47-2.74). The cumulative probability of device infection was higher among patients with defibrillators compared with those with pacemakers, P<.001. Twelve (54.6%) of 22 cases of Staphylococcus aureus BSI had definite or possible cardiac device infection vs 3 (12.0%) of 25 cases of bloodstream infection due to gram-negative bacilli (P=.004).

Conclusions: To our knowledge, this is the first population-based study to describe the incidence of cardiac device infection. Device infection was common during episodes of S aureus BSI. The rate of cardiac device infection was higher in patients with defibrillators than in those with pacemakers.

Arch Intern Med. 2007;167:669-675
diac devices and BSI in Olmsted County, Minnesota. Our aim was to address 2 major unanswered questions in the study of device infection: What is the incidence rate of device infection in patients with BSI, and does this rate differ based on organism or device type?

**METHODS**

**SETTING**

The Rochester Epidemiology Project (REP) is a medical record-linkage system that indexes medical records from all individuals residing in Olmsted County. A single dossier exists for each patient and into it medical diagnoses, surgical interventions, and other key information from medical records are regularly abstracted and entered into computerized indices using the *International Classification of Diseases, Adapted Code for Hospitals*. Because the REP provides access to details of health care of local residents regardless of health provider, accurate incidence data and population-based analytic studies of disease causes and outcomes are possible.

**CASE ASCERTAINMENT**

The Division of Cardiovascular Diseases at Mayo Clinic maintains prospectively collected databases of cardiac device implantations as well as follow-up patient encounters. Because Mayo Clinic is the only institution in Olmsted County that performs cardiac implantation or follows up patients with cardiac devices, virtually all residents of Olmsted County with cardiac devices would have undergone implantation at Mayo Clinic. Patients with cardiac devices implanted elsewhere who then relocated to Olmsted County would be included if they had ever received medical care related to their device. No patients with cardiac resynchronization device were included in the study.

Cases of BSI were identified using several methods. Electronic blood culture data were available from both microbiology laboratories in Olmsted County (for Mayo Clinic from 1983 to the present and Olmsted Medical Center from 2003 to the present) and were matched to cardiac device databases. For study years without electronic data available, we used adapted ICD-9 codes to identify possible or potential BSI cases via adapted ICD-9 codes.

**CASE DEFINITIONS**

Identification of device infection may be challenging for physicians given the wide variety of presenting syndromes and lack of a diagnostic gold standard. We used the definition by Cha-""
denominator, with a population growth rate of 1.9% projected for years after 2000. Person-years at risk were calculated from the date of device implantation to the date of BSI, death, or censoring (for example, if the patient left Olmsted County). The association between BSI, device infection, and survival was examined by Kaplan-Meier survival curves and multivariate Cox regression analysis, adjusting for age, sex, and device type. Fisher exact tests were used for comparison between proportions. The level of significance for all statistical tests was 2-sided, at P < .05. The institutional review boards of both Mayo Clinic and Olmsted Medical Center approved the study.

A total of 1524 patients with cardiac devices were identified in Olmsted County during the study period and were included in the cohort. Patient characteristics are described in Table 1; 1300 patients had PPMs, 203 had defibrillators, and 21 patients had both. The mean (SD) age at device placement was 74.6 (13.5) years overall, although there was a significant difference between mean age of patients with PPMs (76.2 years; 95% confidence interval [CI], 75.5-76.9) and those with defibrillators (64.3 years; 95% CI, 62.4-65.9) (P < .001). Of the PPM recipients, 51% were female, whereas only 19% of defibrillator recipients were female (P < .001).

Incidence of device implantation in Olmsted County (age-adjusted to the population of white individuals in the United States in 2000) over the 30-year period is shown in Figure 1. Total person-time of follow-up from device implantation to time of pocket infection or censoring (infection, death, or censoring) was 4376.7 total device-years of follow-up from time of implantation to time of pocket infection or censoring (incidence rate, 1.37 per 1000 device-years; 95% CI, 0.62-3.05).

Of the 1524 patients in the full 30-year cohort, 78 cases of BSI occurred in 75 unique patients. The incidence of BSI was 10.1 per 1000 device-years (95% CI, 8.1-12.7). Specific organisms are given in Table 2. The most common organisms were *Staphylococcus aureus* (22 cases of BSI [28%]) and *Escherichia coli* (17 cases of BSI [22%]). In 9 cases (40%), *S aureus* isolates were methicillin resistant. Bloodstream infection occurred a median of 1140 days (range, 22-7110 days) after device implantation. The cumulative probability of BSI after device implantation is shown in Figure 2. Suspected sources included the urinary tract (22 cases of BSI [28%]), central venous catheters (12 cases [15%]),

### Table 1. Demographic Characteristics of 1503 Patients With Permanent Pacemaker (PPM) or Defibrillator, 1975-2004*

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>1300 With PPM</th>
<th>203 With Defibrillator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex, No. (%)</td>
<td>632 (49)</td>
<td>165 (81)</td>
</tr>
<tr>
<td>Age at device implant, mean (SD), y</td>
<td>76.2 (12.5)</td>
<td>64.3 (14.4)</td>
</tr>
<tr>
<td>Charlson Comorbidity Index, median (interquartile range)†</td>
<td>3 (2-6)</td>
<td>NA</td>
</tr>
<tr>
<td>Survival after device placement, median, y</td>
<td>6.28</td>
<td>8.93</td>
</tr>
<tr>
<td>Bloodstream infection, No. (%)</td>
<td>63 (4.8)</td>
<td>12 (5.9)</td>
</tr>
</tbody>
</table>

Abbreviation: NA, not available.
*Excluding patients with both PPM and defibrillator.
†The Charlson Comorbidity Index was calculated from administrative databases, as previously described. Data for the Charlson Comorbidity Index were available for only 1146 of the patients with PPM.

### Table 2. Microbiologic Distribution of 78 Bloodstream Infections in 75 Patients With Cardiac Devices

<table>
<thead>
<tr>
<th>Organism</th>
<th>Infections, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>22 (28)</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>17 (22)</td>
</tr>
<tr>
<td>Klebsiella species</td>
<td>7 (9)</td>
</tr>
<tr>
<td>Enterococcus species</td>
<td>6 (8)</td>
</tr>
<tr>
<td>β-Hemolytic streptococci</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Coagulase-negative staphylococci</td>
<td>6 (8)</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>4 (5)</td>
</tr>
<tr>
<td><em>Citrobacter</em> species</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Other*</td>
<td>8 (10)</td>
</tr>
</tbody>
</table>

*Includes viridans-group streptococci, *Pseudomonas aeruginosa*, *Enterobacter cloacae*, *Listeria monocytogenes*, *Bacteroides* species, and *Clostridium* species.

©2007 American Medical Association. All rights reserved.
pneumonia (8 cases [10%]), intra-abdominal (7 cases [9%]), skin or soft-tissue (6 cases [8%]), or other or unknown source (23 cases [30%]). Risk factors and clinical characteristics of the 75 patients with BSI are described in Table 3.

Echocardiography was performed in 33 episodes of BSI (42%), including transesophageal echocardiography in 10 episodes, transthoracic echocardiography in 17 episodes, and both transthoracic and transesophageal in 6 episodes. Six (18%) of the 33 patients who had echocardiograms had vegetations noted on echocardiography, including 2 cases with lead vegetations, 2 with valvular vegetations, and 2 with vegetations on both lead and valve. All patients with vegetations had undergone transesophageal echocardiography; valvular vegetations were seen on the tricuspid valve (2 cases), mitral valve (1 case), and the aortic valve (1 case). None of the 10 patients who had only transthoracic echocardiography had vegetations demonstrated. Six patients (18%) met modified Duke criteria for infective endocarditis.18,19

Seven definite device infections were diagnosed by clinical or microbiologic criteria in patients with BSI. Comparison of clinical features of BSI cases with and without definite device infection is shown in Table 4. Causative organisms included coagulase-negative staphylococci (2 cases), S aureus (4 cases), and enterococci (1 case).

None of the episodes of BSI due to gram-negative bacilli were associated with definite device infection. Two patients with gram-negative BSI developed relapsing bacteremia after cessation of antimicrobial therapy; alternative explanations for relapse other than device infection were noted in both (biliary obstruction due to malignancy in 1 patient and chronic indwelling urinary catheter in the other). Neither of the patients underwent echocardiographic evaluation during their initial BSI.

Of the 22 patients with S aureus BSI, 4 (18%) met criteria for definite device infection vs none of the patients with gram-negative bacilli BSI (P = .04). Two (3%) of 62 patients with PPMs with BSI had device infection vs 5 (36%) of 14 patients with defibrillators (P = .002). Median duration of follow-up after BSI was 252 days (range, 0-4594 days; intraquartile range, 52-1030). Fifty-one (72%) of the patients had a duration of follow-up greater than 12 weeks without evidence of recurrent infection, and a diagnosis of device infection was therefore re-
jected. Of the remaining 20 patients with duration of follow-up of less than 12 weeks, 15 (75%) died while in the hospital. Three had autopsies that showed no evidence of device infection. Two patients (1 with StreptococcusagalactiaeBSI and 1 withS aureusBSI) had evidence of mitral valve infective endocarditis at autopsy but showed no specific histopathologic evidence of cardiac device infection. These 2 patients were classified as having possible device infection; the other 3 with autopsies that were negative for infection were classified as not having device infection.

Comparison of rates of device infection among S aureus, gram-negative bacilli, and other organisms is shown in **Table 5**. The rate of possible or definite device infection in patients with S aureus BSI was 12 (55%) of 22; in patients with BSI owing to gram-negative bacilli, it was 3 (12%) of 25 (P = .004).

Overall, the incidence rate of pocket infection alone was 1.37 per 1000 device-years; the incidence rate of device-related endocarditis or pocket infection with BSI was 1.14 per 1000 device-years. The cumulative probability of device infection is shown in Figure 2. The cumulative probability of device infection was higher among those with a defibrillator compared with those with a PPM (P < .001). The incidence of definite device infection was 1.9 per 1000 device-years (95% CI, 1.1-3.1). The incidence of defibrillator infection was 8.9 (95% CI, 4.2-18.6) per 1000 device-years; the incidence of PPM infection was 1.0 (95% CI, 0.5-2.2) per 1000 device-years (P < .001).

### COMMENT

The present study is the largest to date of infection in patients with cardiac devices and to our knowledge is the first to calculate the incidence of device infection in a population-based setting. This design eliminates the tertiary referral bias typically seen in other studies of device infection. In our large cohort study spanning a 30-year time period of over 7500 device-years of follow-up, the incidence of device infection was 1.9 per 1000 device-years.

To our knowledge, our study is the first to directly compare the incidence of device infection in patients with BSI caused by varying pathogens. The estimated rate of device infection in patients with S aureus BSI was estimated at as much as 54.6%, similar to previously reported investigations. The low risk of device infection among patients with BSI caused by gram-negative bacilli is similar to our previously published non-population-based investigation.28 These findings have profound implications for physicians who care for patients with cardiac devices. It is unclear if differential rates of infection during BSI caused by varying pathogens are due to intrinsic pathogen-related factors (such as adherence factors and biofilm formation), device-specific characteristics, or host factors such as time to BSI after implantation, age, or sex. Previous studies of bacterial adherence to heart valves in vivo found similar differences between gram-positive and gram-negative organisms.31 An alternative explanation is that device infection does occur with BSI due to gram-negative bacilli, but antimicrobial therapy is curative, even if the system is infected and not removed. Understanding the difference in rates of device infection during BSI caused by different organisms may help avoid unnecessary device removal in patients who are device dependent, which is especially important because morbidity and mortality with device removal are well described.1,12,13

Surprisingly, we found that the cumulative probability of device infection was significantly higher in patients with defibrillators compared with those with PPMs. It is unclear if this is due to underlying comorbidities or demographics of patients with defibrillators, differences in device or lead physical properties, or implantation-associated risks (such as increased procedure complexity, length of procedure, or physician volume). Recent data on device exchanges related to manufacturer recalls suggest a higher rate of infection in these patients with BSI due to gram-negative bacilli, but antimicrobial therapy is curative, even if the system is infected and not removed. Understanding the difference in rates of device infection during BSI caused by different organisms may help avoid unnecessary device removal in patients who are device dependent, which is especially important because morbidity and mortality with device removal are well described.1,12,13

### Table 4. Comparison of Demographic and Clinical Features of Device Infection Among 78 Cases of Bloodstream Infection (BSI)*

<table>
<thead>
<tr>
<th>Cases of BSI</th>
<th>Definite Device Infection (n=7)</th>
<th>No Device Infection (n=71)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>5 (71.4)</td>
<td>46 (65.8)</td>
<td>&gt;.99</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>70.8 (16.6)</td>
<td>79.4 (9.9)</td>
<td>.24</td>
</tr>
<tr>
<td>Implantable cardioverter defibrillator</td>
<td>5 (71.4)</td>
<td>9 (12.7)</td>
<td>.002</td>
</tr>
<tr>
<td>&gt;1 Lead</td>
<td>2 (28.6)</td>
<td>42 (59.2)</td>
<td>.23</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>3 (42.8)</td>
<td>16 (22.5)</td>
<td>.35</td>
</tr>
<tr>
<td>Hemodialysis</td>
<td>4 (57.1)</td>
<td>7 (9.8)</td>
<td>.006</td>
</tr>
<tr>
<td>Central venous catheter</td>
<td>4 (57.1)</td>
<td>11 (15.5)</td>
<td>.02</td>
</tr>
<tr>
<td>Malignancy</td>
<td>1 (14.3)</td>
<td>22 (31.0)</td>
<td>.67</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>7 (100)</td>
<td>43 (60.6)</td>
<td>.045</td>
</tr>
<tr>
<td>Prosthetic valve</td>
<td>3 (42.9)</td>
<td>9 (12.7)</td>
<td>.07</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>3 (42.9)</td>
<td>29 (40.9)</td>
<td>.99</td>
</tr>
<tr>
<td>Anticoagulation</td>
<td>0</td>
<td>23 (32.4)</td>
<td>.09</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>5 (71.4)</td>
<td>40 (56.3)</td>
<td>.73</td>
</tr>
<tr>
<td>WBC (&gt;10³/mL), median (95% CI)</td>
<td>11 100</td>
<td>14 500</td>
<td>.17</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; WBC, white blood cell count.
* Data are presented as number (percentage) except where noted.

### Table 5. Comparison of Device Infection Cases Among 78 Cases of Bloodstream Infection (BSI)

<table>
<thead>
<tr>
<th>Device Infection*</th>
<th>Staphylococcus aureus (n=22)</th>
<th>Gram-Negative Bacilli (n=25)</th>
<th>Other Organisms† (n=31)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite</td>
<td>4 (18)</td>
<td>0</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Possible</td>
<td>8 (36)</td>
<td>3 (12)</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Rejected</td>
<td>10 (45)</td>
<td>22 (88)</td>
<td>26 (84)</td>
</tr>
</tbody>
</table>

*P value for difference in rate of device infection between S aureus and gram-negative BSI is .004.
†Definite or possible cases included coagulase-negative staphylococci (2 cases), Enterococcus, Streptococcusagalactiae, and Fusobacterium nucleatum.
patients. Further understanding of the specific risk factors for device infection will be crucial.

The present study has several limitations that are primarily the result of its retrospective design. Olmsted County has relatively homogeneous demographics, which may limit the generalizability to populations underrepresented in the community. Usage of adapted ICD-9 codes for screening of potential cases of BSI has not been previously validated, although the internal validity of our methods seemed to be excellent when compared with computerized microbiology data. Computerized microbiology records were used for Mayo Clinic patients from 1983 to 2005, and therefore ICD-9 codes represented a very small portion of our cases. Transesophageal echocardiography was not performed in all patients (or even available for clinical practice during the early years of our study) and may have been differentially undertaken in patients who were considered to be at higher risk for device infection. We attempted to address this limitation by using criteria, including follow-up without relapse and autopsy findings in deceased patients, to improve case ascertainment. Although the lack of universal echocardiography precludes an exact calculation of the rate of device infection owing to varying pathogens, the long duration of follow-up that is available with a population-based study effectively excluded device infection in most of our patients. Even if device infection were present in all patients who did not undergo echocardiography, it would not have a clinical impact on the treatment of these patients because relapses were uncommon.

Microbiologic techniques, such as the volume of blood collected, number of bottles, duration of incubation, and methods of bacterial identification, have changed over time. It is difficult to assess what impact, if any, this would have had on our study. Only patients whose blood cultures were positive for organisms were included. Patients who may have clinically been considered to have sepsis but whose blood cultures were negative for organisms were therefore not included, nor were those whose cultures were negative for organisms owing to preceding therapy with antimicrobial drugs. Patients with BSI who did not have blood cultures drawn (eg, those who did not seek medical attention or were treated empirically without culture samples) or patients with transient BSI, such as BSI following a medical procedure, would have been missed as well. Our results then would be an underestimation of the true incidence of BSI in this population.

Prior studies have supported the systematic extraction of cardiac devices among patients with device infection, followed by prolonged therapy with antimicrobial drugs prior to device reimplantation at a new site. Our data support the consideration of device infection among patients with S aureus BSI, but device infection, or the necessity for device removal, does not seem to be commonly found in patients with BSI caused by gram-negative bacilli.

Accepted for Publication: December 10, 2006.
Correspondence: Daniel Z. Uslan, MD, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 37-121 CHS, Los Angeles, CA 90095 (duslan@mednet.ucla.edu).

Author Contributions: Study concept and design: Uslan, Sohail, St. Sauver, Hayes, Wilson, Steckelberg, and Baddour. Acquisition of data: Uslan, Sohail, St. Sauver, Friedman, and Hayes. Analysis and interpretation of data: Uslan, Friedman, Hayes, Stoner, Wilson, Steckelberg, and Baddour. Drafting of the manuscript: Uslan and Stoner. Critical revision of the manuscript for important intellectual content: Uslan, Sohail, St. Sauver, Friedman, Hayes, Wilson, Steckelberg, and Baddour. Statistical analysis: Uslan, St. Sauver, and Stoner. Obtained funding: Uslan and Baddour. Administrative, technical, and material support: Sohail. Study supervision: Friedman, Hayes, Wilson, Steckelberg, and Baddour.

Financial Disclosure: Dr Friedman is a consultant for and has received honoraria from Medtronic, Guidant, and Astrazeneca. He has received research funding from Medtronic and from Astrazeneca via Beth Israel Hospital, Guidant, St Jude Medical, and Bard. Dr Friedman has intellectual property rights in Bard EP, Hewlett Packard, and Medical Positioning Inc. Dr Hayes has received honoraria from Medtronic, Boston Scientific, St Jude Medical, and Sorin/ELA Medical; has received research funding from Medtronic; is on the medical advisory boards or committees of St Jude Medical, Sorin/ELA Medical, and AI Semi; is on the steering committees for St Jude Medical and Medtronic; and has conducted sponsored research for Visible Assets. Dr Baddour has received royalty payments from Elsevier and UpToDate and is also an editorial consultant for the American College of Physicians and Physicians’ Information and Education Resource.

Funding/Support: This work was supported in part by the Small Grants Program, Division of Infectious Diseases, Department of Medicine, Mayo Clinic College of Medicine.

Role of the Sponsor: The Division of Infectious Diseases, Department of Medicine, Mayo Clinic, had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Previous Presentation: This study was presented in part at the Infectious Diseases Society of America Annual Meeting; October 13, 2006, Toronto, Ontario.

Acknowledgment: We gratefully acknowledge Imad Tleijeh, MD, for assistance with study design and concept and Kathy Parsons, AA, for administrative support.

REFERENCES


